Evaluation of Ceftaroline Activity versus Daptomycin (DAP) against DAP-Nonsusceptible Methicillin-Resistant Staphylococcus aureus Strains in an In Vitro Pharmacokinetic/Pharmacodynamic Model

被引:23
|
作者
Steed, Molly [1 ]
Vidaillac, Celine [1 ]
Rybak, Michael J. [1 ,2 ]
机构
[1] Wayne State Univ, Eugene Applebaum Coll Pharm & Hlth Sci, Antiinfect Res Lab, Detroit, MI 48201 USA
[2] Wayne State Univ, Sch Med, Detroit, MI 48201 USA
关键词
COMPLICATED SKIN; DOUBLE-BLIND; PHASE-III; CANVAS; VANCOMYCIN-INTERMEDIATE; ANTIMICROBIAL ACTIVITY; SUSCEPTIBILITY; CEPHALOSPORIN; SAFETY; FOSAMIL;
D O I
10.1128/AAC.00347-11
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
The objective of this study was to investigate the potential role of ceftaroline, a new broad-spectrum cephalosporin, as a therapeutic option for the treatment of daptomycin-nonsusceptible (DNS) methicillin-resistant Staphylococcus aureus (MRSA) infections. Four clinical DNS MRSA strains, R5717, R5563, R5996 (heteroresistant vancomycin-intermediate S. aureus) and R5995 (vancomycin-intermediate S. aureus) were evaluated in a two-compartment hollow-fiber in vitro pharmacokinetic/pharmacodynamic model at a starting inoculum of 10(7) CFU/ml for 96 h. Simulated regimens were ceftaroline at 600 mg every 12 h (q12h) (maximum free-drug concentration [fC(max)], 15.2 mu g/ml; serum half-life [t(1/2)], 2.3 h), daptomycin at 6 mg/kg q24h (fC(max), 7.9 mu g/ml; t(1/2), 8 h), and daptomycin at 10 mg/kg q24h (fC(max), 15.2 mu g/ml; t(1/2), 8 h). Differences in CFU/ml between 24 and 96 h were evaluated by analysis of variance with Tukey's post-hoc test. Bactericidal activity was defined as a >= 3-log(10) CFU/ml decrease in the colony count from the initial inoculum. The ceftaroline MIC values were 0.25, 0.5, 0.5, and 0.5 mu g/ml, and the daptomycin MIC values were 2, 2, 4, and 4 mu g/ml for R5717, R5563, R5996, and R5995, respectively. Ceftaroline displayed sustained bactericidal activity against 3 of the 4 strains at 96 h (R5717, -3.1 log(10) CFU/ml; R5563, -2.5 log(10) CFU/ml; R5996, -5.77 log(10) CFU/ml; R5995, -6.38 log(10) CFU/ml). Regrowth occurred during the daptomycin at 6-mg/kg q24h regimen (4 strains) and the daptomycin at 10-mg/kg q24h regimen (3 strains). At 96 h, ceftaroline was significantly more active, resulting in CFU/ml counts lower than those obtained with daptomycin at 6 mg/kg q24h (4 strains, P <= 0.008) and daptomycin at 10 mg/kg q24 h (3 strains, P <= 0.001). Isolates with increased MIC values for daptomycin (all 4 strains) but not for ceftaroline were recovered. Ceftaroline was effective against the 4 isolates tested and may provide a clinical option for the treatment of DNS MRSA infections.
引用
收藏
页码:3522 / 3526
页数:5
相关论文
共 50 条
  • [1] Evaluation of Ceftaroline, Vancomycin, Daptomycin, or Ceftaroline plus Daptomycin against Daptomycin-Nonsusceptible Methicillin-Resistant Staphylococcus aureus in an In Vitro Pharmacokinetic/Pharmacodynamic Model of Simulated Endocardial Vegetations
    Werth, Brian J.
    Barber, Katie E.
    Ireland, Cortney E.
    Rybak, Michael J.
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2014, 58 (06) : 3177 - 3181
  • [2] A combination of ceftaroline and daptomycin has synergistic and bactericidal activity in vitro against daptomycin nonsusceptible methicillin-resistant Staphylococcus aureus (MRSA)
    Shafiq, Iffat
    Bulman, Zackery P.
    Spitznogle, Sarah L.
    Osorio, Justin E.
    Reilly, Irene S.
    Lesse, Alan J.
    Parameswaran, Ganapathi I.
    Mergenhagen, Kari A.
    Tsuji, Brian T.
    INFECTIOUS DISEASES, 2017, 49 (05) : 410 - 416
  • [3] Evaluation of Telavancin Activity versus Daptomycin and Vancomycin against Daptomycin-Nonsusceptible Staphylococcus aureus in an In Vitro Pharmacokinetic/Pharmacodynamic Model
    Steed, Molly E.
    Vidaillac, Celine
    Rybak, Michael J.
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2012, 56 (02) : 955 - 959
  • [4] Evaluation of Ceftaroline Alone and in Combination against Biofilm-Producing Methicillin-Resistant Staphylococcus aureus with Reduced Susceptibility to Daptomycin and Vancomycin in an In Vitro Pharmacokinetic/Pharmacodynamic Model
    Barber, Katie E.
    Smith, Jordan R.
    Ireland, Cortney E.
    Boles, Blaise R.
    Rose, Warren E.
    Rybak, Michael J.
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2015, 59 (08) : 4497 - 4503
  • [5] In vitro activity of ceftaroline against methicillin-resistant Staphylococcus aureus isolates
    Basireddy, S.
    Singh, M.
    Ali, S.
    Kabra, V.
    INDIAN JOURNAL OF MEDICAL MICROBIOLOGY, 2015, 33 (03) : 464 - +
  • [6] In Vitro Activity of Iclaprim against Methicillin-Resistant Staphylococcus aureus Nonsusceptible to Daptomycin, Linezolid, or Vancomycin: A Pilot Study
    Huang, David B.
    Hawser, Stephen
    Gemmell, Curtis G.
    Sahm, Daniel F.
    CANADIAN JOURNAL OF INFECTIOUS DISEASES & MEDICAL MICROBIOLOGY, 2017, 2017
  • [7] Novel Daptomycin Combinations against Daptomycin-Nonsusceptible Methicillin-Resistant Staphylococcus aureus in an In Vitro Model of Simulated Endocardial Vegetations
    Steed, Molly E.
    Vidaillac, Celine
    Rybak, Michael J.
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2010, 54 (12) : 5187 - 5192
  • [8] In vitro activity of ceftaroline: A novel antibiotic against methicillin-resistant Staphylococcus aureus
    Gaikwad, Vaishali
    Gohel, Tejash
    Panickar, Shrijeet
    Chincholkar, Vijay
    Mangalkar, Santosh
    INDIAN JOURNAL OF PATHOLOGY AND MICROBIOLOGY, 2016, 59 (04) : 496 - 498
  • [9] Ceftaroline Increases Membrane Binding and Enhances the Activity of Daptomycin against Daptomycin-Nonsusceptible Vancomycin-Intermediate Staphylococcus aureus in a Pharmacokinetic/Pharmacodynamic Model
    Werth, Brian J.
    Sakoulas, George
    Rose, Warren E.
    Pogliano, Joseph
    Tewhey, Ryan
    Rybak, Michael J.
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2013, 57 (01) : 66 - 73
  • [10] Evaluation of In-Vitro Activity of Ceftaroline Against Methicillin-Resistant Staphylococcus aureus Clinical Isolates
    Roy, Ankita
    Poddar, Nirmala
    Panigrahi, Kumudini
    Pathi, Basanti
    Nayak, Subham Ravi
    Dandapat, Roshni
    Pattnaik, Dipti
    Praharaj, Ashok K.
    Patro, A. Raj Kumar
    CUREUS JOURNAL OF MEDICAL SCIENCE, 2023, 15 (12)